ArticleJournal of clinical medicine2026

Comparative Evaluation of the Effectiveness of Nivolumab Versus Axitinib in the Second-Line Treatment of Patients with Metastatic Renal Cell Carcinoma: A Two-Center Experience.

İrfan Buğday et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.